English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Human infections are a serious public health problem because many pathogens such as bacteria and yeast are becoming increasingly resistant to antibiotics.1 Despite the great advances achieved by science, among the ten main causes of death worldwide, which include ischaemic heart disease, stroke, diarrhea, HIV/ AIDS, malaria, tuberculosis, pre-term birth complications and birth asphyxia and birth trauma, the lower respiratory infections top the list.2 It is estimated that the so called ‘super-microorganisms’ alone will be responsible for over 10 million deaths by 2050, making it imperative the search for alternative treatments to microorganisms which are unresponsive to most modern antibiotics.3 Similarly, opportunistic fungal Objective The aim of this study was to screen a group of medicinal plants’ extracts used in the treatment of ailments related to infections in the Brazilian popular medicine. And to carry out in vivo toxicity and antibacterial studies on Conyza bonariensis (Asteraceae) leaves and roots methanolic extracts selected based on the screening. Methods: Eleven methanolic extracts obtained from nine plants, reportedly used in the treatments of infections from the state of Mato Grosso, Brazil, were initially screened for their in vitro antibacterial and antifungal activities employing disc diffusion and broth micro dilution assays. Preliminary phytochemical analysis was carried out. The most promising extract based on our results and previous literature reports was then evaluated in the in vivo antibacterial activities using mouse model of bacterial infection induced by Staphylococcus aureus and Escherichia coli. In addition, in vivo acute toxicity was conducted to evaluate the safety profile of the extracts. Results: All of the extracts tested were active against at least one of the bacterial and fungal strain tested with activities ranging from moderate to weak. Phytochemical analyses of MECbl and MECbr demonstrated the presence of free steroids and coumarins in MECbl and flavonoids, tanins, free steroids, reduced anthraquinones and coumarins in MECBr. Oral administration of MECbl and MECbr up to 5000 mg/kg did not provoked any toxicological events in the mice, thus suggesting that the LD50 is higher than 5000 mg/kg. In vivo antibacterial assay demonstrated superior prophylactic activity of MECbl compared to MECbr. Conclusion: MECbl and MECbr are safe when administered acute orally at doses up to 5000 mg/kg. Methanolic extracts of Conyza bonariensis possessed in vitro antibacterial and antifungal activities. Considerable in vivo antibacterial activities were observed in bacterial infection model for both MECbl and MECbr, effects comparable to that of meropenem, in some cases. Both extracts present in common free steroids and coumarins. The current in vivo antibacterial activity study further lend supports to the use of Conyza bonariensis in the treatment of infections in many traditional medicines. Cristiane Coimbra de Paula1*, Domingos Tabajara De Oliveira Martins1, Karuppusamy Arunachalam1, Sikiru Olaitan Balogun1, 2, Quessi Irias Borges1, Marcelo Garcia Picone1, Wander Miguel de Barros3, Regilane Matos da Silva Prado 1, 4

pharmacognosy journal

Antimicrobial Screening of Medicinal Plants Popularly used in Mato Grosso for Treating Infections: Advances on the Evaluation of Conyza bonariensis (L.) Cronquist in vitro and in vivo Antibacterial Activities